[Sildenafil in the treatment of pulmonary hypertension]

Area of Science:

• Pediatric Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Pulmonary hypertension (PHT) is a severe condition with limited treatment options, particularly in pediatric cases.
• Congenital heart defects like mitral stenosis and persistent ductus arteriosus can lead to complex PHT.
• Conventional therapies often prove insufficient for severe, persistent pediatric PHT.

Observation:

• An infant with PHT secondary to congenital mitral stenosis and PDA experienced persistent symptoms despite surgical correction.
• The patient developed congestive cardiac failure and refractory PHT, unresponsive to standard treatments.
• Sildenafil, a phosphodiesterase type 5 inhibitor, was administered as a salvage therapy.

Findings:

• Sildenafil treatment led to a satisfactory clinical course, enabling extubation and discontinuation of vasoactive drugs.
• Hemodynamic improvements were observed, including decreased pulmonary and left atrial pressures.
• The infant was discharged on oral sildenafil and maintained a stable condition during outpatient follow-up.

Implications:

• Sildenafil represents a viable therapeutic option for refractory pediatric pulmonary hypertension, especially when associated with congenital heart disease.
• This case highlights the potential of targeted pharmacotherapy in managing complex pediatric cardiovascular conditions.
• Further research into PDE5 inhibitors for pediatric PHT is warranted to establish optimal protocols and long-term efficacy.